Therapeutic Novelties in the New ACC 2026 Acute Pulmonary Embolism Guideline

Professor Geoffrey D. Barnes examines the therapeutic innovations introduced in the new ACC 2026 Acute Pulmonary Embolism Guideline, focusing on updated treatment protocols and novel anticoagulation strategies presented at the ACC 2026 Annual Congress.

Efficacy and Safety of Sotatercept in PH-HFpEF: Results From the Phase 2 CADENCE Trial

Professor Mardi Gomberg-Maitland presents the results from the Phase 2 CADENCE trial, investigating the efficacy and safety of Sotatercept in patients with combined post- and pre-capillary pulmonary hypertension associated with heart failure with preserved ejection fraction (HFpEF).

Mavacamten in Symptomatic Adolescent Patients With Obstructive HCM: Results From the Phase 3 Scout-HCM Trial

Professor Joseph William Rossano presents the highly anticipated results from the Phase 3 Scout-HCM trial, evaluating the efficacy and safety of Mavacamten in symptomatic adolescent patients living with obstructive hypertrophic cardiomyopathy at the ACC 2026 Annual Congress.

Pulmonary Embolism in 2026: A Case-Based Journey From Diagnosis to Recovery

Prof. Stanislav Henkin and Prof. Daniella Kadian-Dodov lead a comprehensive, case-based exploration of pulmonary embolism management in 2026, tracking the patient journey from initial diagnosis through to long-term recovery strategies at the ACC 2026 Annual Congress.

Kardinal: A Phase 2 Study of Tonlamarsen For the Treatment of Uncontrolled Hypertension

Dr. Luke Laffin presents the results of the Kardinal Phase 2 study, investigating the efficacy of Tonlamarsen as a novel treatment option for patients with uncontrolled hypertension at the ACC 2026 Annual Congress.

Meet the Experts: 2025 High Blood Pressure Guideline

Professor Keith C. Ferdinand joins a panel of experts to discuss the practical implementation and clinical implications of the 2025 High Blood Pressure Guideline at the ACC 2026 Annual Congress.

Acute Pulmonary Embolism Guideline 2026

Professor Gregory Piazza provides an expert overview of the newly released 2026 Acute Pulmonary Embolism Guideline, focusing on critical updates in diagnosis and management at the ACC 2026 Annual Congress.

2025 High Blood Pressure Guideline

Professor Daniel Jones joins a panel of distinguished specialists to provide expert commentary on the 2025 High Blood Pressure Guideline, focusing on evidence-based strategies for clinical implementation at the ACC 2026 Annual Congress.

Discontinuation of β-blocker Therapy in Stabilized Patients After Acute Myocardial Infarction

Professor Joo-Yong Hahn presents critical insights on the discontinuation of beta-blocker therapy in stabilized patients following an acute myocardial infarction, discussing the clinical implications and trial findings at the ACC 2026 Annual Congress.

Next-Generation Lipid Treatment Options

Professor Robert S. Rosenson explores the evolving landscape of lipid management, detailing next-generation treatment options and their potential to transform cardiovascular risk reduction at the ACC 2026 Annual Congress.

Effects of Tirzepatide vs. Dulaglutide on Cardiorenal Outcomes: SURPASS-CVOT Analysis

Professor Steven E. Nissen presents a critical analysis of the SURPASS-CVOT data, comparing the effects of Tirzepatide and Dulaglutide on expanded cardiorenal outcomes in patients at high cardiovascular risk at the ACC 2026 Annual Congress.

An Update on Cardiac Prevention Medications: Hypertension and Incretin in Focus

Professor Peter P. Toth provides a comprehensive update on the latest pharmacological strategies in cardiac prevention, specifically focusing on the evolving roles of hypertension management and incretin-based therapies at the ACC 2026 Annual Congress.

Highlights of the 2026 ACC/AHA Dyslipidemia Guideline

Professor Carol F. Kirkpatrick highlights the most critical updates and clinical recommendations from the 2026 ACC/AHA Dyslipidemia Guideline, focusing on new management targets and therapeutic strategies for lipid disorders at the ACC 2026 Annual Congress.

Saving Women's Hearts

Professor Roxana Mehran addresses the critical need for gender-specific approaches in cardiovascular care, discussing strategies and clinical advancements aimed at saving women's hearts at the ACC 2026 Annual Congress.

2026 Acute Pulmonary Embolism Guideline

Professor Mark A. Creager provides an in-depth overview of the newly released 2026 Acute Pulmonary Embolism Guideline, highlighting key updates in clinical management and patient outcomes at the ACC 2026 Annual Congress.

Highlights of ACC.26

Professor Christopher Kramer shares the most significant breakthroughs, late-breaking clinical trials, and key takeaways from the ACC 2026 Annual Congress, summarizing the future of cardiovascular care.

CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study

SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry

ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study

PURE: Impact of modifiable risk factors on cardiovascular disease and mortality

RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial

Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease

AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial

Salt substitution and community-wide reduction in blood pressure and hypertension incidence

HOPE 4 - Impact on cardiovascular risk of a community based multifaceted intervention in individuals with hypertension in 2 middle income countries: The Heart Outcomes Prevention and Evaluation 4 study

SYNTAXES: Ten-Year Survival after Coronary Artery Bypass Grafting versus Percutaneous Coronary Intervention: The SYNTAX Extended Survival study

MITRA-FR - 2 years follow-Up of the MITRA-FR study a randomized controlled trial evaluating the effectiveness of percutaneous mitral valve repair in secondary mitral regurgitation

DAPA HF The Dapagliflozin And Prevention Of Adverse-outcomes In Heart Failure Trial

CONDI-2/ERIC-PPCI Effect of remote ischemic conditioning on clinical outcomes in patients with Stsegment elevation myocardial infarction undergoing primary percutaneous coronary intervention